CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||100 mg and 200 mg|
|Indication||ROS1-positive Non-Small Cell Lung Cancer|
|Funding Request||For the first-line treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer|
|Pre Noc Submission||Yes|
|NOC Date||May 5, 2020|
|Manufacturer||Hoffmann-La Roche Ltd.|
|Sponsor||Hoffmann-La Roche Ltd.|
|Submission Date||January 8, 2020|
|Submission Deemed Complete||January 22, 2020|
|Stakeholder Input Deadline ‡||January 22, 2020|
|Check-point meeting||March 25, 2020|
|pERC Meeting||December 17, 2020|
|Initial Recommendation Issued||January 8, 2021|
|Feedback Deadline ‡||January 22, 2021|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued||January 27, 2021|
|Notification to Implement Issued||February 11, 2021|
|Therapeutic Area||ROS1-positive NSCLC|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.